扶正抗癌方联合常规化疗在非小细胞肺癌术后患者中的应用效果  

Application effects of Fuzheng anticancer prescription combined with conventional chemotherapy in postoperative patients with non-small cell lung cancer

作　　者：范文强[1] 高新芳[1] FAN Wenqiang;GAO Xinfang(Second District of Cardiothoracic Surgery of Jiaozuo Second People’s Hospital,Jiaozuo 454001 Henan,China)

机构地区：[1]焦作市第二人民医院心胸外科二区,河南焦作454001

出　　处：《中国民康医学》2023年第4期126-128,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察扶正抗癌方联合常规化疗在非小细胞肺癌(NSCLC)术后患者中的应用效果。方法:选取2017年6月至2019年6月该院收治的100例NSCLC术后患者进行前瞻性研究,按照随机数字表法分为观察组与对照组各50例。对照组采用常规化疗,观察组在对照组基础上联合扶正抗癌方治疗,比较两组中医证候积分、血清炎性因子[C反应蛋白(CRP)、白细胞介素-1(IL-1)和降钙素原(PCT)]水平和血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)]水平。结果:治疗后,两组中医证候积分及血清CRP、IL-1、PCT、CEA、CA125、NSE、CYFRA21-1水平均低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。结论:扶正抗癌方联合常规化疗应用于NSCLC术后患者可降低中医证候积分、炎性因子水平和肿瘤标志物水平,效果优于单纯常规化疗。Objective:To observe application effects of Fuzheng Anticancer prescription combined with conventional chemotherapy in postoperative patients with non-small cell lung cancer(NSCLC).Methods:A prospective study was conducted on 100 patients with NSCLC admitted to the hospital from June 2017 to June 2019.They were divided into observation group and control group according to the random number table method,50cases in each.The control group was treated with conventional chemotherapy,while the observation group was treated with Fuzheng anticancer prescription on the basis of that of the control group.The TCM syndrome scores,the serum inflammatory factors[C-reactive protein(CRP),interleukin-1(IL-1)and procalcitonin(PCT)]levels,and the serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),neuron-specific enolase(NSE),cytokeratin 19 fragment(CYFRA21-1)]levels were compared between the two groups.Results:After the treatment,the TCM syndrome scores and the levels of serum CRP,IL-1,PCT,CEA,CA125,NSE and CYFRA21-1 in the two groups were lower than those before the treatment,those of the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusions:Fuzheng anticancer prescription combined with conventional chemotherapy can reduce the TCM syndrome score,the inflammatory factor levels and the tumor marker levels in postoperative patients with NSCLC.Moreover,it is superior to single conventional chemotherapy.

关 键 词：扶正抗癌方 非小细胞肺癌 肺功能 中医证候积分 炎性因子 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]